arrow_back Back to App

Curbing drug patent extensions: faster access to cheaper generics.

The REMEDY Act aims to limit pharmaceutical companies' practices of artificially extending drug exclusivity by filing multiple related patents. It introduces a rule that only one selected patent can trigger the 30-month stay on the approval of cheaper generic drugs. This means that after the law takes effect, new generic drugs may enter the market faster, potentially lowering healthcare costs for citizens.
Key points
Changes in drug approval: For new drugs, only one patent, selected by the manufacturer, can delay the introduction of cheaper generic alternatives.
Faster generic access: Limiting the ability to block the market with multiple patents is intended to speed up access to cheaper drug versions, benefiting patients and health insurance systems.
Applies to new drugs: The new rules apply to drugs approved on or after the date the Act is enacted.
article Official text account_balance Process page
Expired
Citizen Poll
No votes cast
Additional Information
Print number: 118_S_4878
Sponsor: Sen. Durbin, Richard J. [D-IL]
Process start date: 2024-07-31
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-flash-latest
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

REMEDY Act

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 118_S_4878.

Which chamber initiated this legislation?

This legislation was initiated in the Senate.

When did the legislative process begin?

The process officially started on 2024-07-31.

What are the main provisions?

Key points include:

  • Changes in drug approval: For new drugs, only one patent, selected by the manufacturer, can delay the introduction of cheaper generic alternatives.
  • Faster generic access: Limiting the ability to block the market with multiple patents is intended to speed up access to cheaper drug versions, benefiting patients and health insurance systems.
  • Applies to new drugs: The new rules apply to drugs approved on or after the date the Act is enacted.
What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Sen. Durbin, Richard J. [D-IL].

What is the latest detailed status?

The latest detailed status is: Introduced in Senate

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-26.

CATEGORIES

Health Economy Courts and Law